Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy
NCT02241395Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Aug 2013
- Primary completion
- Jun 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in cerebral palsy (CP), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: change in clinical symptoms at 2 years. Planned start Aug 2013; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT02241395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241395.